Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04687969 · ClinicalTrials.gov registry record
Multimodal Machine Learning Characterization of Solid Tumors
A clinical trial of Prostate Cancer and Glioma, sponsored by Ciprian Catana, MD, PhD.
- Active
- Registry status
- 135
- Enrollment target
- 2
- Study locations
NCT04687969: Active study of Prostate Cancer and Glioma, sponsored by Ciprian Catana, MD, PhD.
NCT04687969 is a study of Prostate Cancer and Glioma that is active but no longer recruiting, run by Ciprian Catana, MD, PhD. The registered enrollment target is 135 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04687969, a study of Prostate Cancer and Glioma, is active but no longer recruiting, sponsored by Ciprian Catana, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Primary Outcome
First tumor aggressiveness will be identified by binarizing the Gleason grade scores (GG ≥ 3+4). Binarized tumor aggressiveness obtained from the machine learning techniques will be then compared to the gold-standard, histopathology.
Conditions Studied
Interventions
- DRUG [18F]DCFPyL
- RADIATION PET/MRI scanner
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2022-10-23 |
| Est. Completion | 2025-12-31 |
What the registry record for NCT04687969 still lists
NCT04687969 is an observational study that tracks outcomes without assigning an intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (78% lower).
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which [18F]DCFPyL is the first listed.
NCT04687969 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04687969 about?
NCT04687969 is a clinical study titled "Multimodal Machine Learning Characterization of Solid Tumors". This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness. This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
What is the current status of trial NCT04687969?
This trial is currently active not recruiting. The enrollment target is 135 participants. The study started on 2022-10-23. Estimated completion is 2025-12-31.
What conditions does trial NCT04687969 study?
This clinical trial studies the following conditions: Prostate Cancer, Glioma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Radical Prostatectomy.
What interventions are being tested in trial NCT04687969?
The interventions under investigation include: [18F]DCFPyL (DRUG), PET/MRI scanner (RADIATION).
Who is sponsoring clinical trial NCT04687969?
This trial is sponsored by Ciprian Catana, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04687969 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04687969's enrollment target sits among peer trials
135 284th of 735 higher than 451 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI